Stopping prostate cancer from becoming invasive
Preventing invasive prostate cancer
['FUNDING_R01'] · UNIVERSITY OF NEBRASKA MEDICAL CENTER · NIH-11211073
This work tests a new medicine called KBU2046 that aims to stop early prostate cancer cells from moving and becoming invasive.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEBRASKA MEDICAL CENTER (nih funded) |
| Locations | 1 site (OMAHA, UNITED STATES) |
| Trial ID | NIH-11211073 on ClinicalTrials.gov |
What this research studies
From a patient's view, researchers are developing a new drug, KBU2046, designed to block the movement of prostate cancer cells so tumors are less likely to invade surrounding tissue. In the lab they will pinpoint exactly where the drug binds in cells and use tools like computer modeling, biochemical tests, and special probes that lock onto the drug's target. They will also study how the drug affects a key signaling pathway (involving Raf1 and related proteins) that controls cell movement in human prostate cells. Work includes rigorous preclinical tests that support plans for later safety studies required to move the drug toward clinical trials.
Who could benefit from this research
Good fit: Ideal candidates would be men with early-stage or localized prostate cancer or high-risk pre-invasive prostate lesions who might benefit from a prevention-focused therapy.
Not a fit: Men with already metastatic or widely advanced prostate cancer are unlikely to benefit from this prevention-focused approach.
Why it matters
Potential benefit: If successful, the drug could prevent early prostate cancers from progressing to invasive, life-threatening disease and reduce the need for aggressive treatments.
How similar studies have performed: This is a first-in-class, novel approach with promising preclinical and IND-enabling data but has not yet been tested in people.
Where this research is happening
OMAHA, UNITED STATES
- UNIVERSITY OF NEBRASKA MEDICAL CENTER — OMAHA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERGAN, RAYMOND C. — UNIVERSITY OF NEBRASKA MEDICAL CENTER
- Study coordinator: BERGAN, RAYMOND C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.